Influence of "priming" on the potency of non-depolarizing neuromuscular blocking agents. 1987

M M Brady, and R K Mirakhur, and F M Gibson
Department of Anaesthetics, Queen's University of Belfast, N. Ireland.

Dose-response curves have been constructed to determine the ED50 and ED95 (doses required to produce a 50% and a 95% block, respectively) following administration of a small "priming" dose of atracurium 50 micrograms kg-1, vecuronium 10 micrograms kg-1 or pancuronium 10 micrograms kg-1. The myoneural blockers were administered subsequently as a single bolus. The results were compared with previously published work on these drugs, in which no priming dose had been administered. The respective ED50 and ED95 values in the primed and control groups were 122 and 126 micrograms kg-1 and 208 and 226 micrograms kg-1, respectively, for atracurium; 26 and 23 micrograms kg-1 and 42 and 39 micrograms kg-1, respectively, for vecuronium; and 31 and 30 micrograms kg-1 and 56 and 60 micrograms kg-1, respectively, for pancuronium. The values showed no significant differences between the respective primed and control groups. Contrary to previous suggestions, our results show no enhancement of blockade when these drugs were administered in divided doses.

UI MeSH Term Description Entries
D009466 Neuromuscular Blocking Agents Drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. They can be of two types, competitive, stabilizing blockers (NEUROMUSCULAR NONDEPOLARIZING AGENTS) or noncompetitive, depolarizing agents (NEUROMUSCULAR DEPOLARIZING AGENTS). Both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc. Neuromuscular Blocker,Neuromuscular Blocking Agent,Neuromuscular Blockers,Agent, Neuromuscular Blocking,Agents, Neuromuscular Blocking,Blocker, Neuromuscular,Blockers, Neuromuscular,Blocking Agent, Neuromuscular,Blocking Agents, Neuromuscular
D009469 Neuromuscular Junction The synapse between a neuron and a muscle. Myoneural Junction,Nerve-Muscle Preparation,Junction, Myoneural,Junction, Neuromuscular,Junctions, Myoneural,Junctions, Neuromuscular,Myoneural Junctions,Nerve Muscle Preparation,Nerve-Muscle Preparations,Neuromuscular Junctions,Preparation, Nerve-Muscle,Preparations, Nerve-Muscle
D010197 Pancuronium A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than CURARE but has less effect on the circulatory system and on histamine release. Pancuronium Bromide,Pancuronium Curamed,Pancuronium Organon,Pavulon,Bromide, Pancuronium
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001279 Atracurium A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents. Atracurium Besylate,Atracurium Dibesylate,33 A 74,Atracurium Besilate,BW-33A,Relatrac,Tracrium,A 74, 33,BW 33A,BW33A,Besilate, Atracurium
D013810 Therapeutic Equivalency The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease. Bioequivalence,Clinical Equivalency,Equivalency, Therapeutic,Generic Equivalency,Clinical Equivalencies,Equivalencies, Clinical,Equivalencies, Therapeutic,Equivalency, Clinical,Therapeutic Equivalencies,Bioequivalences,Equivalencies, Generic,Equivalency, Generic,Generic Equivalencies
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014673 Vecuronium Bromide Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents. NC-45,Norcuron,ORG-NC 45,ORG-NC-45,ORG-NC45,Vecuronium,Vecuronium Bromide, Quaternary Ion,Vecuronium Citrate,Vecuronium Hydrobromide,Vecuronium Hydrochloride,Vecuronium Maleate,Vecuronium Phosphate,Bromide, Vecuronium,Citrate, Vecuronium,Hydrobromide, Vecuronium,Hydrochloride, Vecuronium,Maleate, Vecuronium,NC 45,NC45,ORG NC 45,ORG NC45,ORGNC 45,ORGNC45,Phosphate, Vecuronium

Related Publications

M M Brady, and R K Mirakhur, and F M Gibson
January 1974, Wisconsin medical journal,
M M Brady, and R K Mirakhur, and F M Gibson
December 1982, Wiadomosci lekarskie (Warsaw, Poland : 1960),
M M Brady, and R K Mirakhur, and F M Gibson
February 1982, British journal of anaesthesia,
M M Brady, and R K Mirakhur, and F M Gibson
November 1991, British journal of anaesthesia,
M M Brady, and R K Mirakhur, and F M Gibson
May 2019, JA clinical reports,
M M Brady, and R K Mirakhur, and F M Gibson
January 1972, Experientia,
M M Brady, and R K Mirakhur, and F M Gibson
February 2005, Canadian journal of anaesthesia = Journal canadien d'anesthesie,
M M Brady, and R K Mirakhur, and F M Gibson
June 1984, British journal of anaesthesia,
M M Brady, and R K Mirakhur, and F M Gibson
July 1999, Current opinion in anaesthesiology,
Copied contents to your clipboard!